JWCAR239 for B-cell lymphoma that has returned
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR T-cell therapy called JWCAR239 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. It aims to see if this personalized immune cell treatment can help shrink tumors and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lymphoma must be a type that tests positive for CD20 or CD19 markers (like diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, etc.).
- You must have tried at least 2 prior treatments that didn't work, or your lymphoma came back after a stem cell transplant using your own cells.
- You need to have at least one tumor that can be seen on a CT scan (node >1.5 cm or other site >1 cm).
- Your overall health should be good enough to handle the treatment (good blood counts, kidney, liver, heart, and lung function).
- You cannot have active infections like hepatitis B, hepatitis C, or HIV, or a history of certain other cancers (unless they've been cured for over 2 years).
- You must not have had prior treatment with CAR T-cells or other gene-modified T-cells, or an allogeneic stem cell transplant (from a donor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.